A Phase 3 interventional study of Valsartan and Enalapril in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-07-12.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.
Among the 140 studies testing valsartan in Hypertension, this one is the 62nd largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 77th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →
Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
140 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 5 · Phase 3 54 · Phase 4 67
First in 2001; this study’s year is marked. 12 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 198 across the 139 interventional studies. Of the 126 that completed or were terminated, 29 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 140 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
227 studies in Hypertension by Novartis: 4 open now, 5 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 227 studies in Hypertension by Novartis, this one is the 124th largest by enrollment of the 222 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 117th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 140 studies testing valsartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 227 in Hypertension:
This tab as a report to print or save as PDF → With an account.
The purpose of this extension study is to compare the long-term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril alone in children with hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Valsartan · Drug: Enalapril
Drug: Enalapril · Drug: placebo matched to valsartan
Drug: Valsartan · Drug: placebo matched to enalapril
Drug: Enalapril · Drug: placebo matched to valsartan
Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
Number of Patients With Adverse Events
Time frame: Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients)
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.
Time frame: Core Baseline (Week 0) to Week 26
Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26
Systolic and diastolic blood pressure (BP) control was defined as msSBP and msDBP \< 95th percentile for gender, age, and height. After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.
Time frame: Week 26
Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20
24-hour ambulatory blood pressure monitoring (ABPM) was conducted once during the extension in a subset of patients at selected centers. For all patients who completed a qualifying ABPM at baseline, an ABPM was to be performed at Week 20. The ABPM monitor was placed on the non-dominant arm.
Time frame: Core Baseline (Week 0) to Week 20
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.
Time frame: Core Baseline (Week 0) to Week 26
| Milestone | CKD Patients: Valsartan+Enalapril | CKD Patients: Enalapril | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril |
|---|---|---|---|---|
| Started | 21 | 17 | 103 | 109 |
| Completed | 11 | 15 | 96 | 103 |
| Not completed | 10 | 2 | 7 | 6 |
| Withdrew: Adverse event | 7 | 2 | 3 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 |
| Withdrew: Administrative problems | 3 | 0 | 4 | 1 |
| Participants | CKD Patients: Valsartan+Enalapril | CKD Patients: Enalapril | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril |
|---|---|---|---|---|
| Number of Patients With Adverse Events | 16 | 11 | 51 | 53 |
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.
| mmHg | CKD Patients: Valsartan+Enalapril | CKD Patients: Enalapril | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril |
|---|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26 | -20.4 ± 11.48 | -11.7 ± 9.55 | -7.5 ± 8.47 | -7.2 ± 8.99 |
Systolic and diastolic blood pressure (BP) control was defined as msSBP and msDBP \< 95th percentile for gender, age, and height. After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.
| Percentage of patients | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril |
|---|---|---|
| Systolic BP control | 66.0 | 63.0 |
| Diastolic BP control | 95.1 | 91.7 |
24-hour ambulatory blood pressure monitoring (ABPM) was conducted once during the extension in a subset of patients at selected centers. For all patients who completed a qualifying ABPM at baseline, an ABPM was to be performed at Week 20. The ABPM monitor was placed on the non-dominant arm.
| mmHg | CKD Patients: Valsartan+Enalapril | CKD Patients: Enalapril | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril |
|---|---|---|---|---|
| Systolic BP | -23.3 ± 11.60 | -0.3 ± 14.42 | -11.5 ± 7.81 | -4.1 ± 11.49 |
| Diastolic BP | -17.8 ± 3.20 | 2.9 ± 10.81 | -12.2 ± 6.60 | -4.5 ± 7.59 |
After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.
| mmHg | CKD Patients: Valsartan+Enalapril | CKD Patients: Enalapril | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril |
|---|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26 | -23.6 ± 10.79 | -18.2 ± 9.51 | -11.6 ± 9.74 | -10.2 ± 9.70 |
Collected over Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CKD Patients: Valsartan+Enalapril | — | 7/21 (33.3%) | 14/21 (66.7%) |
| Non-CKD Patients: Valsartan | — | 1/103 (1%) | 25/103 (24.3%) |
| CKD Patients: Enalapril | — | 0/17 (0%) | 11/17 (64.7%) |
| Non-CKD Patients: Enalapril | — | 2/109 (1.8%) | 42/109 (38.5%) |
| Event | CKD Patients: Valsartan+Enalapril | Non-CKD Patients: Valsartan | CKD Patients: Enalapril | Non-CKD Patients: Enalapril |
|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 3/21 | 0/103 | 0/17 | 0/109 |
| Kidney transplant rejectionImmune system disorders | 1/21 | 0/103 | 0/17 | 0/109 |
| PyelonephritisInfections and infestations | 1/21 | 0/103 | 0/17 | 0/109 |
| White blood cell count decreasedInvestigations | 1/21 | 0/103 | 0/17 | 0/109 |
| SynostosisMusculoskeletal and connective tissue disorders | 1/21 | 0/103 | 0/17 | 0/109 |
| HypotensionVascular disorders | 1/21 | 0/103 | 0/17 | 0/109 |
| Adrenogenital syndromeCongenital, familial and genetic disorders | 0/21 | 1/103 | 0/17 | 0/109 |
| GastroenteritisInfections and infestations | 0/21 | 0/103 | 0/17 | 1/109 |
| SyncopeNervous system disorders | 0/21 | 0/103 | 0/17 | 1/109 |
| Event | CKD Patients: Valsartan+Enalapril | Non-CKD Patients: Valsartan | CKD Patients: Enalapril | Non-CKD Patients: Enalapril |
|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 4/21 | 0/103 | 2/17 | 3/109 |
| HeadacheNervous system disorders | 4/21 | 11/103 | 1/17 | 16/109 |
| PyrexiaGeneral disorders | 3/21 | 5/103 | 0/17 | 4/109 |
| PharyngitisInfections and infestations | 2/21 | 7/103 | 2/17 | 11/109 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/21 | 2/103 | 2/17 | 1/109 |
| VomitingGastrointestinal disorders | 2/21 | 0/103 | 0/17 | 3/109 |
| Urinary tract infectionInfections and infestations | 2/21 | 1/103 | 1/17 | 2/109 |
| DizzinessNervous system disorders | 2/21 | 1/103 | 0/17 | 1/109 |
| HypotensionVascular disorders | 2/21 | 0/103 | 0/17 | 0/109 |
| NasopharyngitisInfections and infestations | 0/21 | 6/103 | 1/17 | 9/109 |
| Age Continuous(years) | CKD Patients: Valsartan+Enalapril | CKD Patients: Enalapril | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril | Total |
|---|---|---|---|---|---|
| Mean | 11.4 ± 3.40 | 12.1 ± 3.07 | 13.1 ± 2.75 | 13.3 ± 2.81 | 13.0 ± 2.89 |
| Sex: Female, Male(Participants) | CKD Patients: Valsartan+Enalapril | CKD Patients: Enalapril | Non-CKD Patients: Valsartan | Non-CKD Patients: Enalapril | Total |
|---|---|---|---|---|---|
| Female | 8 | 5 | 41 | 27 | 81 |
| Male | 13 | 12 | 62 | 82 | 169 |
The record gives a start of Jun 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Valsartan · Enalapril